For Immediate Release
Chicago, IL – November 21, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Procter & Gamble Co. (
PG Quick Quote PG - Free Report) , Novartis AG ( NVS Quick Quote NVS - Free Report) , Mondelez International, Inc. ( MDLZ Quick Quote MDLZ - Free Report) , Elevance Health, Inc. ( ELV Quick Quote ELV - Free Report) and Vertex Pharmaceuticals Inc. ( VRTX Quick Quote VRTX - Free Report) . Here are highlights from Monday’s Analyst Blog: Top Stock Reports for Procter & Gamble, Novertis and Mondelez
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co., Novartis AG and Mondelez International, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>> Procter & Gamble's shares have outperformed the Zacks Soap and Cleaning Materials industry over the past year (+7.3% vs. +5.3%). The company has been gaining from robust pricing and a favorable mix, along with strength across segments. It has been focused on productivity and cost-saving plans to boost margins. This led to the top and bottom lines beating the consensus mark for the fifth consecutive quarter in the first quarter of fiscal 2024. Consequently, PG has provided an optimistic fiscal 2024 view. However, the company has been witnessing supply-chain issues, higher SG&A costs, higher transportation costs and rising inflation. Its significant international presence exposes it to foreign currency risks, which acts as a headwind. (You can ) read the full research report on Procter & Gamble here >>> Shares of Novartis have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+18.7% vs. +12.0%). The company's third-quarter results were better than expected as drugs like Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio continued to fuel growth and offset the impact of generic competition. Pluvicto and Scemblix have witnessed solid launches and Leqvio's launch continues to progress. With the separation of Sandoz, Novartis has become a pure-play pharmaceutical company. The acquisition of Chinook Therapeutics has strengthened its renal pipeline. However, generic competition for key drugs like Gilenya and pipeline setbacks remain concerns. (You can ) read the full research report on Novartis here >>> Shares of Mondelez International have outperformed the Zacks Food - Miscellaneous industry over the past year (+9.7% vs. -11.3%). The company, which has been seeing solid organic revenues, has been benefiting from strength in emerging markets and its core chocolate and biscuit categories. It has also been focused on strengthening areas with higher growth potential via prudent buyouts (like Clif Bar) and divestitures. These upsides, together with pricing actions, fueled third-quarter 2023 results, wherein management raised its 2023 organic net revenue and earnings guidance. However, Mondelez has been battling challenges related to global cost inflation. The company continues to anticipate double-digit inflation in 2023. Volatile currency movements and competitive pressure also pose concerns. Other noteworthy reports we are featuring today include Elevance Health, Inc, and Vertex Pharmaceuticals Inc. Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of
+46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation. See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.